Central Amygdala to Lateral Hypothalamus Neuropeptide Y projections as a Target in Sex-Specific Binge-Like Ethanol Consumption in Mice

中央杏仁核到外侧下丘脑神经肽 Y 的预测作为小鼠性别特异性暴饮暴食样乙醇消耗的目标

基本信息

项目摘要

PROJECT SUMMARY Heavy alcohol use and dependence has become a major public health concern within the United States and across the globe, with limited treatments currently available to those who seek them. Binge intake of alcohol is a significant risk factor to the development of dependence, and this form of intake leads to major health consequences. While men are more commonly diagnosed with alcohol use disorders, the frequency for diagnoses in females has risen in recent years. Furthermore, sex differences in drinking behavior and the underlying neural mechanism remain largely unknown. Our lab, and others, have implicated the role of the central amygdala (CeA) in ethanol consumption in animal models. Corticotrophin releasing factor (CRF) modulates binge-like ethanol drinking in the CeA, and pilot data from our lab shows that silencing CRF+ projections from the CeA to the lateral hypothalamus (LH) leads to a sex-specific reduction of binge-like ethanol drinking in male, but not female, mice. Similarly, CRF1R antagonism and CRF2R agonism in the LH lead to male specific blunting of binge-drinking, suggesting this receptor system’s involvement in modulating binge drinking. CRF, GABA, and Neuropeptide Y (NPY) Y1 receptor (Y1R) are all closely expressed in the CeA, and pilot work from our lab shows Y1R activation in the CeA blunts binge-like ethanol intake, similar to effects seen in males with silenced CRF neurons in the CeA. However, sex-dependent ethanol consumption differences in the NPY system remain uninvestigated. Thus, this proposal focuses on examining potential sex-differences in CeA NPY and Y1R signaling, as well as the role of the Y1R+ CeA  LH pathway, in the modulation of binge-like ethanol consumption. Proposed experiments will use a combination of transgenic, chemogenetic, histological, and pharmacological approaches. The well-validated rodent model of binge-like ethanol consumption known as “Drinking in the Dark” (DID) will be used throughout these experiments to identify neural changes. For Aim 1, I will use the designer receptor technology (viral injections of Cre-dependent Y1R-promoter DREADDs in the CeA) and cannulation of the LH in transgenic NPY1R-cre mice to determine if silencing Y1R+ projection neurons from the CeA to the LH will attenuate DID binge-like ethanol intake and associated blood ethanol concentrations (BECs) in male but not female mice. In Aim 2, I will focus on the role of Y1R signaling in the CeA, and whether Y1R agonism can affect binge-like ethanol drinking in a sex-dependent manner, using site-directed pharmacology and an NPY over-expressing viral vector. Lastly, in Aim 3, I will examine changes in NPY and Y1R levels, and co-expression with CRF, after multiple cycles of binge-like ethanol drinking in male and female mice. Binge-induced plasticity in the NPY system that are sex- dependent are predicted, and will be assessed using immunohistochemistry, Western Blots, and real-time PCR to quantify protein and mRNA in the CeA. Taken together, these results will provide new insights into the neurocircuitry underlying sex-differences in binge-like ethanol intake.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sophie Charlotte Bendrath其他文献

Sophie Charlotte Bendrath的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sophie Charlotte Bendrath', 18)}}的其他基金

Central Amygdala to Lateral Hypothalamus Neuropeptide Y projections as a Target in Sex-Specific Binge-Like Ethanol Consumption in Mice
中央杏仁核到外侧下丘脑神经肽 Y 的预测作为小鼠性别特异性暴饮暴食样乙醇消耗的目标
  • 批准号:
    10537002
  • 财政年份:
    2022
  • 资助金额:
    $ 3.92万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 3.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 3.92万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 3.92万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 3.92万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 3.92万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 3.92万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 3.92万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 3.92万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 3.92万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 3.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了